HIGHLIGHT
Idacio

Idacio Indications/Uses

adalimumab

Manufacturer:

Fresenius Kabi

Distributor:

Zuellig Pharma
The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Indications/Uses
ADULTS: Rheumatoid Arthritis: IDACIO is indicated for reducing signs and symptoms, inducing major clinical response and clinical remission, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
IDACIO can be used alone or in combination with methotrexate or other disease modifying anti-rheumatic drugs (DMARDs).
Psoriatic Arthritis: IDACIO is indicated for reducing signs and symptoms of active arthritis in adult patients with psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis.
IDACIO can be used alone or in combination with DMARDs.
Axial Spondyloarthritis: Ankylosing Spondylitis: IDACIO is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
Non-radiographic Axial spondyloarthritis (Axial Spondyloarthritis without radiographic evidence of AS): IDACIO is indicated for reducing signs and symptoms in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) but with objective signs of inflammation by evaluated CRP and/or MRI, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs.
Plaque Psoriasis: IDACIO is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate.
Crohn's Disease: IDACIO is indicated for the treatment of moderately to severely active Crohn's disease in adult patients who have had an inadequate response to conventional therapy. IDACIO is also indicated for treatment in adult patients with moderately to severely active Crohn's Disease who have lost response to or are intolerant to infliximab.
Ulcerative Colitis: IDACIO is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
Hidradenitis Suppurativa: IDACIO is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy.
Uveitis: IDACIO is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.
PEDIATRICS: Juvenile Idiopathic Arthritis: Polyarticular Juvenile Idiopathic Arthritis: IDACIO in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA), in patients aged above 2 years of age who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). IDACIO can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.
Enthesitis-Related Arthritis: IDACIO is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant to, conventional therapy.
Pediatric Crohn's Disease: IDACIO is indicated for the treatment of moderately to severely active Crohn's disease in pediatric patients (6 to 17 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroids, and/or an immunomodulator, or who are intolerant to or have contraindication for such therapies.
Pediatric Plaque Psoriasis: IDACIO is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapy.
Pediatric Uveitis: IDACIO is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.
Adolescent Hidradenitis Suppurativa: IDACIO is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic hidradenitis suppurativa (HS) therapy.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in